Outcome Measures in Interventional Trials for Prevention or Treatment of Venous Thrombosis in the Pediatric Population

ABSTRACT

Determining clinically relevant outcomes are one of the key issues in the design of clinical trials. Recently, a working group from the Perinatal and Pediatric Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis published a position article defining outcomes in interventional trials for prevention and treatment of deep vein thrombosis (DVT) in children. For these studies the primary efficacy outcomes are DVT and the primary safety outcomes are bleeding. The exact definitions for these outcomes are included in this review article. This article expands on these recommendations by summarizing and reviewing the current literature in pediatric anticoagulation studies; discussing the relationship of choice of outcomes to specific clinical trial design; providing a more detailed discussion on the rationale for the defined outcomes in pediatric anticoagulation trials, as well as a detailed examination of secondary and tertiary outcomes. With a growing interest in multicenter, multinational pediatric anticoagulation clinical trials, establishment of standardized outcome measures that are applied uniformly over all studies is critically important. Agreement from the international academic community on these outcomes is an important step in assuring well-designed clinical trials, which are implemented to optimize the prevention and treatment of DVT in children.

KEYWORDS

Outcome measures - interventional trials - pediatrics - deep vein thrombosis

REFERENCES

• 1 Massicotte P, Julian J A, Gent M PROTEKT Study Group et al. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial.  Thromb Res. 2003;  109 (2-3) 101-108
• 2 Massicotte P, Julian J A, Gent M REVIVE Study Group et al. An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial.  Thromb Res. 2003;  109 (2-3) 85-92
• 3 Mitchell L, Andrew M, Hanna K et al.. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study.  Thromb Haemost. 2003;  90 (2) 235-244
• 4 Alton G Y, Robertson C M, Sauve R Western Canadian Complex Pediatric Therapies Project Follow-Up Group et al. Early childhood health, growth, and neurodevelopmental outcomes after complete repair of total anomalous pulmonary venous connection at 6 weeks or younger.  J Thorac Cardiovasc Surg. 2007;  133 (4) 905-911
• 5 Kuhle S, Massicotte P, Dinyari M et al.. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events.  Thromb Haemost. 2005;  94 (6) 1164-1171
• 6 Ruud E, Holmstrøm H, De Lange C, Hogstad E M, Wesenberg F. Low-dose warfarin for the prevention of central line-associated thromboses in children with malignancies—a randomized, controlled study.  Acta Paediatr. 2006;  95 (9) 1053-1059
• 7 Schroeder A R, Axelrod D M, Silverman N H, Rubesova E, Merkel E, Roth S J. A continuous heparin infusion does not prevent catheter-related thrombosis in infants after cardiac surgery.  Pediatr Crit Care Med. 2010;  11 (4) 489-495
• 8 Young G, Tarantino M D, Wohrley J, Weber L C, Belvedere M, Nugent D J. Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis.  J Thromb Haemost. 2007;  5 (8) 1654-1659
• 9 Mitchell L G, Goldenberg N A, Male C, Kenet G, Monagle P, Nowak-Göttl U. on behalf of the Perinatal and Paediatric Haemostasis Subcommittee of the SSC of the ISTH . Definition of clinical efficacy and safety outcomes for clinical trials in deep venous thrombosis and pulmonary embolism in children.  J Thromb Haemost. 2011;  9 (9) 1856-1858
• 10 Lensing A W, Hirsh J, Buller H R. Diagnosing venous thrombosis. In: Venous Thrombosis. Philadelphia: J.B. Lippincott; 1994: 1297-1321
• 11 Molloy W, English J, O'Dwyer R, O'Connell J. Clinical findings in the diagnosis of proximal deep vein thrombosis.  Ir Med J. 1982;  75 (4) 119-120
• 12 Mitchell L G, Andrew M, Hanna K Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase Group (PARKAA) et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.  Cancer. 2003;  97 (2) 508-516
• 13 Lensing A W, Büller H R, Prandoni P et al.. Contrast venography, the gold standard for the diagnosis of deep-vein thrombosis: improvement in observer agreement.  Thromb Haemost. 1992;  67 (1) 8-12
• 14 Prandoni P, Polistena P, Bernardi E et al.. Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications.  Arch Intern Med. 1997;  157 (1) 57-62
• 15 Lensing A W, Prandoni P, Brandjes D et al.. Detection of deep-vein thrombosis by real-time B-mode ultrasonography.  N Engl J Med. 1989;  320 (6) 342-345
• 16 Baarslag H J, van Beek E J, Koopman M M, Reekers J A. Prospective study of color duplex ultrasonography compared with contrast venography in patients suspected of having deep venous thrombosis of the upper extremities.  Ann Intern Med. 2002;  136 (12) 865-872
• 17 Male C, Chait P, Ginsberg J S et al.. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: results of the PARKAA study. Prophylactic Antithrombin Replacement in Kids with ALL treated with Asparaginase.  Thromb Haemost. 2002;  87 (4) 593-598
• 18 Baarslag H J, Koopman M M, Reekers J A, van Beek E J. Diagnosis and management of deep vein thrombosis of the upper extremity: a review.  Eur Radiol. 2004;  14 (7) 1263-1274
• 19 Kuhle S, Spavor M, Massicotte P et al.. Prevalence of post-thrombotic syndrome following asymptomatic thrombosis in survivors of acute lymphoblastic leukemia.  J Thromb Haemost. 2008;  6 (4) 589-594
• 20 Kuhle S, Koloshuk B, Marzinotto V et al.. A cross-sectional study evaluating post-thrombotic syndrome in children.  Thromb Res. 2003;  111 (4-5) 227-233
• 21 van Ommen C H, Ottenkamp J, Lam J et al.. The risk of postthrombotic syndrome in children with congenital heart disease.  J Pediatr. 2002;  141 (4) 582-586
• 22 Goldenberg N A, Knapp-Clevenger R, Manco-Johnson M J. Mountain States Regional Thrombophilia Group . Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children.  N Engl J Med. 2004;  351 (11) 1081-1088
• 23 Goldenberg N A, Durham J D, Knapp-Clevenger R, Manco-Johnson M J. A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children.  Blood. 2007;  110 (1) 45-53
• 24 Kreuz W, Stoll M, Junker R et al.. Familial elevated factor VIII in children with symptomatic venous thrombosis and post-thrombotic syndrome: results of a multicenter study.  Arterioscler Thromb Vasc Biol. 2006;  26 (8) 1901-1906
• 25 Schobess R, Düring C, Bidlingmaier C, Heinecke A, Merkel N, Nowak-Göttl U. Long-term safety and efficacy data on childhood venous thrombosis treated with a low molecular weight heparin: an open-label pilot study of once-daily versus twice-daily enoxaparin administration.  Haematologica. 2006;  91 (12) 1701-1704
• 26 Sharathkumar A A, Pipe S W. Post-thrombotic syndrome in children: a single center experience.  J Pediatr Hematol Oncol. 2008;  30 (4) 261-266
• 27 van Ommen C H, Heijboer H, van den Dool E J, Hutten B A, Peters M. Pediatric venous thromboembolic disease in one single center: congenital prothrombotic disorders and the clinical outcome.  J Thromb Haemost. 2003;  1 (12) 2516-2522
• 28 Galanis T, Thomson L, Palladino M, Merli G J. New oral anticoagulants.  J Thromb Thrombolysis. 2011;  31 (3) 310-320
• 29 Nowak-Göttl U, Dietrich K, Schaffranek D et al.. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.  Blood. 2010;  116 (26) 6101-6105
• 30 Streif W, Andrew M, Marzinotto V et al.. Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients.  Blood. 1999;  94 (9) 3007-3014
• 31 Anton N, Cox P N, Massicotte M P et al.. Heparin-bonded central venous catheters do not reduce thrombosis in infants with congenital heart disease: a blinded randomized, controlled trial.  Pediatrics. 2009;  123 (3) e453-e458